Testicular germ cell tumors Cell Models for Research

Testicular germ cell tumors (TGCT) are the most common malignancy in men aged 15-44 years, with an estimated global incidence of 74,000 new cases and 9,000 deaths in 2022 (WHO GLOBOCAN). The incidence has been rising in many countries over the past decades. Risk factors include cryptorchidism, family history, and testicular dysgenesis syndrome. With modern cisplatin-based chemotherapy, the 5-year survival rate exceeds 95% for localized disease but drops to around 70% for metastatic disease (NCI SEER). Despite high overall cure rates, a subset of patients develop resistance to chemotherapy, and long-term survivors face significant treatment-related morbidity. This highlights the need for better understanding of TGCT biology and the development of targeted therapies.

TGCTs are unique in their pluripotency and differentiation capacity, making them an excellent model for studying germ cell development, pluripotency, and somatic differentiation. They are broadly classified into seminomas and non-seminomas, with non-seminomas further divided into embryonal carcinoma, yolk sac tumor, choriocarcinoma, and teratoma. This heterogeneity provides a rich system for studying cell fate decisions. Public datasets such as TCGA (The Cancer Genome Atlas) and GEO provide extensive genomic and transcriptomic data, facilitating in silico analyses. Key open questions include the molecular mechanisms of cisplatin resistance, the role of pluripotency factors in tumorigenesis, and the identification of novel therapeutic targets.

TGCT pathogenesis is closely linked to aberrant germ cell development. The following pathways are critical:

• • KIT/KITLG signaling: Activating mutations in KIT (e.g., D816V) and overexpression of its ligand KITLG are common in seminomas, promoting survival and proliferation of primordial germ cells.
• • Pluripotency network: Transcription factors such as OCT4 (POU5F1), NANOG, and SOX2 are essential for maintaining the undifferentiated state of embryonal carcinoma cells. Their dysregulation contributes to tumor growth and differentiation block.
• • p53 pathway: TP53 mutations are rare in TGCT, but the pathway is often functionally inactivated via overexpression of MDM2 or loss of p14ARF, leading to resistance to apoptosis.
• • MAPK/PI3K pathways: Constitutive activation of RAS/RAF/MEK/ERK and PI3K/AKT/mTOR signaling is common, often downstream of KIT mutations, driving proliferation and survival.

Data from TCGA and COSMIC databases.

Key signaling networks in TGCT include:

• • KIT signaling: KIT activation leads to downstream activation of PI3K/AKT, JAK/STAT, and MAPK pathways. Mutations in KIT are common in seminomas.
• • PI3K/AKT/mTOR: This pathway is frequently activated due to KIT mutations, PIK3CA mutations, or PTEN loss. It promotes cell growth, survival, and metabolism.
• • MAPK/ERK: RAS/RAF/MEK/ERK cascade is activated by KIT or RAS mutations, driving proliferation.
• • Pluripotency network: OCT4, NANOG, and SOX2 form a core regulatory network that maintains the undifferentiated state. Their expression is regulated by various signaling pathways including LIF/STAT3 and BMP/SMAD.
• • Apoptosis pathways: Dysregulation of p53 and BCL2 family members contributes to resistance to chemotherapy.

Organoid models of TGCT have been developed from patient-derived samples and can recapitulate the histology and molecular features of the original tumor. They are useful for drug testing and studying tumor-stroma interactions.

Animal models for TGCT include:

• • Patient-derived xenografts (PDX): Tumor fragments from patients are implanted into immunodeficient mice. They preserve the original tumor's heterogeneity and are used for drug efficacy testing.
• • Genetically engineered mouse models (GEMM): Mice with conditional knockout of genes such as Pten or overexpression of KIT mutants have been generated to study TGCT pathogenesis.
• • Induced models: Chemical induction with agents like busulfan or radiation can induce testicular tumors in mice, but these are less specific.
• • Syngeneic models: Mouse TGCT cell lines (e.g., F9) can be transplanted into syngeneic mice for immune-competent studies.

Gene-edited cell models are powerful tools for studying TGCT biology. Using CRISPR/Cas9 technology, researchers can create isogenic cell lines with specific genetic alterations, such as:

• • Knockout lines: For example, a TP53 knockout in NTERA-2 cells to study p53 pathway function.
• • Knock-in lines: Introduction of oncogenic mutations like KIT D816V into wild-type cell lines to model seminoma.
• • Reporter lines: Tagging endogenous genes with fluorescent reporters (e.g., OCT4-GFP) to track pluripotency.

These models are commercially available from various sources, ensuring sequence verification and quality control. They enable precise functional studies and drug screening, accelerating research.

Gene-edited cells are essential for functional genomics. For example:

• • Knockout of tumor suppressors: Knocking out TP53 in NTERA-2 cells can reveal its role in apoptosis and chemotherapy response.
• • Knock-in of oncogenes: Introducing KIT D816V into TCam-2 cells can help study the oncogenic signaling pathways.
• • CRISPR screens: Genome-wide knockout screens in TGCT cell lines can identify genes essential for survival, proliferation, or drug resistance.

Isogenic cell line pairs (wild-type vs. mutant) are invaluable for drug screening. For example:

• • Cisplatin resistance: By knocking out genes involved in DNA repair (e.g., MLH1) or apoptosis (e.g., BAX), researchers can study mechanisms of resistance.
• • Targeted therapy: Isogenic lines with KIT mutations can be used to test KIT inhibitors (e.g., imatinib) and identify resistance mechanisms.
• • Combination screening: Gene-edited cells can be used to identify synergistic drug combinations.

CRISPR-based synthetic lethality screens can identify novel biomarkers and therapeutic targets. For example:

• • Synthetic lethal partners: Knocking out a gene in a background of another mutation can reveal dependencies that can be exploited therapeutically.
• • Reporter lines: Gene-edited reporter lines can be used to monitor pathway activation in high-throughput screens.
• • Resistance biomarkers: By generating resistant cell lines through chronic drug exposure, researchers can identify genetic and epigenetic changes that serve as biomarkers.